New radioactive antibody treatment before stem cell transplant for blood cancers

Plain-English translation of NCT03128034 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new treatment called 211At-BC8-B10, a radioactive antibody designed to target and kill leukemia cells before patients receive a stem cell transplant from a donor. The goal is to see if this medication can improve outcomes for people with hard-to-treat blood cancers by preparing the body better before the transplant and reducing the chance the cancer comes back.

People with advanced blood cancers often don't survive long-term with standard treatments alone. This trial exists to find out whether this new radioactive antibody can make stem cell transplants more effective by delivering cancer-fighting radiation directly to leukemia cells while minimizing harm to healthy cells.

Do you qualify?

You likely qualify if…

you have been diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia that is high-risk, refractory, recurrent, or in early remission with evidence of remaining disease
you are between 18 and 75 years old
you have a matched donor available—either a related family member or an unrelated donor through a national registry
your kidney function is adequate (creatinine clearance greater than 50 mL/min)
your liver and bone marrow function are normal or near-normal
you are in good enough health to tolerate a stem cell transplant (ECOG performance status less than 2)

You likely don't qualify if…

you have an active, uncontrolled infection
you have abnormal liver or kidney function outside the acceptable range
you have had a previous stem cell transplant with ongoing graft-versus-host disease or are still taking immunosuppressive drugs for it
you have significant iron buildup in your liver
your blast cell count is very high (above 10,000 cells per cubic millimeter and cannot be controlled with medication)

What participation looks like

You would receive the new radioactive antibody treatment intravenously over 6–8 hours about one week before your stem cell transplant. You may also receive additional preparatory chemotherapy and low-dose radiation in the days before transplant. On day 0, you receive the stem cell infusion. After transplant, you take medications by mouth or IV for several months to prevent rejection and graft-versus-host disease. You return for follow-up visits at 100 days, then at 6, 9, 12, 18, and 24 months after transplant, with blood tests and possibly bone marrow samples to monitor your recovery.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

New radioactive antibody treatment before stem cell transplant for blood cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations